These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11254118)

  • 1. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M; Caubet JF; McGarry R
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
    Young AM; Marsden J; Goodman A; Burton A; Dunn JA
    Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma.
    Xin Y; Huang Q; Zhang P; Yang M; Hou XY; Tang JQ; Zhang LZ; Jiang G
    Medicine (Baltimore); 2016 Apr; 95(16):e3406. PubMed ID: 27100429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
    Jiang G; Li RH; Sun C; Liu YQ; Zheng JN
    PLoS One; 2014; 9(12):e111920. PubMed ID: 25502446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapy for malignant melanoma.
    Legha SS
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
    Teimouri F; Nikfar S; Abdollahi M
    Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
    Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of melanoma].
    Dréno B; Wallon-Dumont G
    Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE; Agarwala S; Middleton MR
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.